🔴 UroGen Pharma is trading 10.1% down in pre-market after Q3 earnings miss and lower JELMYTO guidance

UroGen Pharma is trading 10.1% lower at $30.92 after its November 4 third-quarter results missed estimates for total revenue and earnings, while management lowered JELMYTO guidance.

• ZUSDURI revenue was $68.0 million, beating estimates and rising 35% sequentially; JELMYTO revenue fell to $21.0 million.
• The company reported a $0.03-per-share loss, versus the expected $0.11 profit.
• The report was scheduled before the market open, with an earnings call at 10:00 a.m. ET; healthcare’s pre-market advance contrasted with the stock’s decline.